IV BAL101553: Phase I/IIa started

Basilea began an open-label, dose-escalation, dose-expansion, Swiss Phase I/IIa trial to evaluate IV BAL101533 as a 48-hour continuous infusion in up to 82 patients who failed standard therapy or for ...